Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch Asia Focus: Pfenex Licenses Asian Rights To Forteo Copy To NT Pharma Group

Executive Summary

Otsuka obtains Japanese rights to two cancer gene therapy candidates from Takara. GlaxoSmithKline extends its protein degradation collaboration with Kymera.

You may also be interested in...



Sanofi Nabs Kymera IRAK4 Protein Degrader As It Continues To Build In I&I

Kymera will receive $150m upfront from Sanofi in a deal the big pharma views as an opportunity to develop a breakthrough oral drug for atopic dermatitis and other conditions.

Vertex Targeting Protein Degradation In $1bn Kymera Deal

Vertex and Kymera will use insights into the ubiquitin-proteasome pathway, for sending unwanted proteins off to recycling, to discover new drug candidates.

World First Korea Darbepoetin Biosimilar Approval To Speed CKD's Global Entry?

With a global first marketing authorization for its darbepoetin biosimilar in South Korea, Chong Kun Dang aims to speed up the product’s entry into the Japanese and other international markets and progress clinical rials with other biosimilars and novel biologics.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel